Publications by authors named "S Atagi"
Objectives: There is limited consensus on resectability criteria for Stage IIIA-N2 non-small cell lung cancer (NSCLC). We examined the patient characteristics, N2 status, treatment decisions, and clinical outcomes according to the treatment modality for Stage IIIA-N2 NSCLC in Japan.
Materials And Methods: Patients with Stage IIIA-N2 NSCLC in Japan were consecutively registered in the SOLUTION study between 2013 and 2014.
Background: We conducted a randomize phase II study to evaluate the efficacy and safety of topoisomerase II inhibitor amrubicin plus topoisomerase I inhibitor irinotecan (AI) compared with cisplatin plus irinotecan (PI) as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer (SCLC).
Patients And Methods: Chemo-naïve patients with pathologically proven ED-SCLC (including limited disease (LD) SCLC with malignant effusion) were enrolled. Patients were randomized 1:1 to receive either AI (amrubicin 90mg/m on day 1 and irinotecan 50mg/m on days 1 and 8 of a 21-day cycle) or PI (cisplatin 60mg/m on day 1 and irinotecan 60mg/m on days 1, 8 and 15 of a 28-day cycle).
Article Synopsis
- The hemagglutinating virus of Japan envelope (HVJ-E) is an inactivated virus that has shown promise in treating chemotherapy-resistant malignant pleural mesothelioma (MPM) by inducing antitumor immunity.
- A phase I clinical study focused on determining a suitable dosage and evaluating the preliminary efficacy of HVJ-E, finding that higher doses resulted in better disease control rates compared to lower doses.
- The study concluded that HVJ-E is safe for patients and appears to have some antitumor activity, leading to plans for a phase II trial with higher dosages.
Article Synopsis
- * A retrospective analysis of 650 NSCLC patients was conducted using machine learning models to assess the relationship between the number of dissected lymph nodes and recurrence risk, with the random forest model showing the best predictive performance.
- * Results indicate that dissecting around 10 lymph nodes minimizes recurrence risk, while dissecting more than 20 nodes significantly increases that risk, suggesting a careful approach to lymph node dissection during surgery.
Article Synopsis
- This study examines the effects of perioperative therapies on treatment outcomes for Japanese patients with clinical stage III non-small cell lung cancer (NSCLC), analyzing data from the SOLUTION study involving 149 patients who started treatment between 2013-2014.
- Results showed that patients who received surgery combined with perioperative therapy had significantly better overall survival (29.3 months vs. not reached) and 3-year survival rates (44.0% vs. 61.1%) compared to those who had surgery alone.
- The analysis indicates that perioperative therapy is linked to improved overall survival, progression-free survival, and disease-free survival, suggesting its importance in enhancing treatment outcomes for NSCLC patients